GlassScriptPhysician profile
Joanna Gammons
NPI 1255371670
$6,337.81
in general payments reported to CMS, 2019-2025
32 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $400 · 2021: $455 · 2022: $787 · 2023: $1,136 · 2024: $1,271 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,522 · Education: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,521.58 |
| Education | $400.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,136.05 | 2021-2025 | |
| Abbvie INC. | $1,053.69 | 2019-2025 | |
| Janssen Biotech, INC. | $1,030.41 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $822.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $582.00 | 2020-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $216.27 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $191.41 | 2019-2024 | Bimzelx |
| Fresenius Kabi USA, LLC | $170.41 | 2023 | Idacio |
| Lilly USA, LLC | $114.29 | 2019-2025 | Ebglyss, Taltz |
| Pfizer INC. | $105.16 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $103.90 | 2023-2024 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Leo Pharma INC. | $89.98 | 2022-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.83 | 2022-2024 | Cyltezo |
| Dermira, INC. | $59.29 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.04 | 2019-2020 | |
| Organon LLC | $56.74 | 2023-2025 | Vtama, Hadlima |
| Incyte Corporation | $43.29 | 2022-2024 | Opzelura |
| Krystal Biotech INC | $39.79 | 2025 | Vyjuvek |
| Almirall LLC | $35.96 | 2019-2020 | |
| Epi Health, LLC | $35.67 | 2019 | |
| Sun Pharmaceutical Industries INC. | $34.18 | 2019 | |
| Arcutis Biotherapeutics, INC. | $33.89 | 2025 | Zoryve |
| Solta Medical, A Division of Bausch Health US, LLC | $27.75 | 2024 | |
| Kyowa Kirin, INC. | $21.68 | 2021 | |
| Genentech USA, INC. | $20.22 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.66 | 2023 | Ycanth |
| Sebela Pharmaceuticals INC. | $16.91 | 2020 | |
| Sandoz INC. | $16.50 | 2020 | |
| Janssen Scientific Affairs, LLC | $15.20 | 2019 | |
| Biofrontera INC. | $14.42 | 2020 | |
| Amgen INC. | $13.88 | 2023 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Gammons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.